Adial Pharmaceuticals ROCE 2024

Adial Pharmaceuticals Aktienanalyse

What does Adial Pharmaceuticals do?

Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Adial Pharmaceuticals's Return on Capital Employed (ROCE)

Adial Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Adial Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Adial Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Adial Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Adial Pharmaceuticals stock

What is the ROCE (Return on Capital Employed) of Adial Pharmaceuticals this year?

The ROCE of Adial Pharmaceuticals is -1.69 undefined this year.

How has the ROCE (Return on Capital Employed) of Adial Pharmaceuticals developed compared to the previous year?

The ROCE of Adial Pharmaceuticals has increased by -58.59% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Adial Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Adial Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Adial Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Adial Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Adial Pharmaceuticals impact the company?

An increase in the ROCE of Adial Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Adial Pharmaceuticals affect the company?

A decrease in ROCE of Adial Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Adial Pharmaceuticals?

Some factors that can affect Adial Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Adial Pharmaceuticals so important for investors?

The ROCE of Adial Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Adial Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Adial Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Adial Pharmaceuticals pay?

Over the past 12 months, Adial Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adial Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adial Pharmaceuticals?

The current dividend yield of Adial Pharmaceuticals is .

When does Adial Pharmaceuticals pay dividends?

Adial Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adial Pharmaceuticals?

Adial Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adial Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adial Pharmaceuticals located?

Adial Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adial Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adial Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Adial Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Adial Pharmaceuticals in the year 2023?

In the year 2023, Adial Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adial Pharmaceuticals pay out the dividend?

The dividends of Adial Pharmaceuticals are distributed in USD.